Benzimidazoles Concept

subject area of

• 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Academic Article
• A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery  Academic Article
• A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN)  Academic Article
• A logical approach to surgical thromboprophylaxis  Academic Article
• A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191  Academic Article
• A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200  Academic Article
• A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group  Academic Article
• A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study  Academic Article
• Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials  Academic Article
• Acid suppression in healthy subjects following lansoprazole or pantoprazole  Academic Article
• Activated prothrombin complex concentrate for dabigatran-associated bleeding  Academic Article
• Acute Precipitants of Congestive Heart Failure Exacerbations  Academic Article
• Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes  Academic Article
• Acute management of bleeding in patients on novel oral anticoagulants  Academic Article
• Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk  Academic Article
• Additional Events in the RE-LY Trial  Academic Article
• Adherence to anticoagulant treatment with dabigatran in a real‐world setting  Academic Article
• Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial  Academic Article
• Advances in treatment and management  Academic Article
• Advantages and limitations of the new anticoagulants  Academic Article
• Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction  Academic Article
• Albuminuria and Rapid Loss of GFR and Risk of New Hip and Pelvic Fractures  Academic Article
• Albuminuria in chronic heart failure: prevalence and prognostic importance  Academic Article
• Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)  Academic Article
• Analysis of Upper Gastrointestinal Adverse Events Among Patients Given Dabigatran in the RE-LY Trial  Academic Article
• Angiotensin-receptor blockers in prevention of cardiovascular events: are they as effective as angiotensin-converting enzyme inhibitors?  Academic Article
• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer  Academic Article
• Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer  Academic Article
• Antithrombotic Therapy for Atrial Fibrillation  Academic Article
• Approach to the new oral anticoagulants in family practice: part 1: comparing the options.  Academic Article
• Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.  Academic Article
• Arterial stiffness and pharmacological interventions--the TRanscend arterial stiffNess Substudy (TRANS study).  Academic Article
• Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke  Academic Article
• Assessing the impact of dabigatran and warfarin on health-related quality of life: Results from an RE-LY sub-study  Academic Article
• Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure  Academic Article
• Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction  Academic Article
• Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation  Academic Article
• Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme  Academic Article
• Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme  Academic Article
• Beyond Unfractionated Heparin and Warfarin  Academic Article
• Bleeding and antidotes in new oral anticoagulants  Academic Article
• Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)  Academic Article
• Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies  Academic Article
• Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease  Academic Article
• Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease  Academic Article
• Body Mass Index and Prognosis in Patients With Chronic Heart Failure  Academic Article
• Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens  Academic Article
• Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter  Academic Article
• Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough  Academic Article
• Candesartan for the management of heart failure: more than an alternative  Academic Article
• Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design  Academic Article
• Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk  Academic Article
• Causes of Death and Influencing Factors in Patients With Atrial Fibrillation  Academic Article
• Changes in Renal Function in Patients With Atrial Fibrillation  Academic Article
• Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM  Academic Article
• Clinical Characteristics and Outcomes of Young and Very Young Adults With Heart Failure  Academic Article
• Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure  Academic Article
• Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program  Academic Article
• Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial  Academic Article
• Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme  Academic Article
• Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications  Academic Article
• Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development  Academic Article
• Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?  Academic Article
• Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure  Academic Article
• Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure  Academic Article
• Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis  Academic Article
• Compound- and fiber type-selective requirement of AMPKγ3 for insulin-independent glucose uptake in skeletal muscle  Academic Article
• Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial  Academic Article
• Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure  Academic Article
• Control of vascular changes by renin–angiotensin–aldosterone system in salt-sensitive hypertension  Academic Article
• Controlling Gene Expression in Living Cells Through Small Molecule-RNA Interactions  Academic Article
• Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist  Academic Article
• Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation  Academic Article
• Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective  Academic Article
• Dabigatran Etexilate  Academic Article
• Dabigatran Etexilate: Future Directions in Anticoagulant Treatment  Academic Article
• Dabigatran Versus Warfarin  Academic Article
• Dabigatran Versus Warfarin in Patients With Atrial Fibrillation  Academic Article
• Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation  Academic Article
• Dabigatran and risk of myocardial infarction  Academic Article
• Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management  Academic Article
• Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?  Academic Article
• Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial  Academic Article
• Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE‐LY trial  Academic Article
• Dabigatran efficacy‐safety assessment for stroke prevention in patients with atrial fibrillation  Academic Article
• Dabigatran etexilate for prevention of venous thromboembolism  Academic Article
• Dabigatran for patients with a mechanical valve  Academic Article
• Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial  Academic Article
• Dabigatran in Patients with Mechanical Heart Valves  Academic Article
• Dabigatran monitoring made simple?  Academic Article
• Dabigatran versus Warfarin for Venous Thromboembolism  Academic Article
• Dabigatran versus Warfarin in Patients with Atrial Fibrillation  Academic Article
• Dabigatran versus Warfarin in Patients with Mechanical Heart Valves  Academic Article
• Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism  Academic Article
• Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada  Academic Article
• Dabigatran versus warfarin in patients with mechanical heart valves: reply  Academic Article
• Dabigatran-Induced Acute Hepatitis  Academic Article
• Dabigatran-related coagulopathy: when can we assume the effect has “worn off”?  Academic Article
• Dabigatran: ready for prime time?  Academic Article
• Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program  Academic Article
• Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction  Academic Article
• Diet and Kidney Disease in High-Risk Individuals With Type 2 Diabetes Mellitus  Academic Article
• Differences in Ischemic and Hemorrhagic Recurrence Rates among Race-Ethnic Groups in the PRoFESS Secondary Stroke Prevention Trial  Academic Article
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials  Academic Article
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.  Academic Article
• Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies  Academic Article
• Early Relief of Upper Gastrointestinal Dyspeptic Symptoms: A Survey of Empirical Therapy with Pantoprazole in Canadian Clinical Practice  Academic Article
• Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients  Academic Article
• Effect of Telmisartan on Functional Outcome, Recurrence, and Blood Pressure in Patients With Acute Mild Ischemic Stroke  Academic Article
• Effect of Telmisartan on Renal Outcomes  Academic Article
• Effect of candesartan on New York Heart Association functional classResults of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme  Academic Article
• Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure  Academic Article
• Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial  Academic Article
• Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes  Academic Article
• Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease  Academic Article
• Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study  Academic Article
• Effects of blood pressure and lipid lowering on cognition  Academic Article
• Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial  Academic Article
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial  Academic Article
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial  Academic Article
• Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme  Academic Article
• Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker  Academic Article
• Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease  Academic Article
• Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals  Academic Article
• Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial  Academic Article
• Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation  Academic Article
• Efficacy and Safety of Dabigatran Compared to Warfarin in Patients With Paroxysmal, Persistent, and Permanent Atrial Fibrillation  Academic Article
• Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial -  Academic Article
• Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) programme  Academic Article
• Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial  Academic Article
• Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy  Academic Article
• Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart fa  Academic Article
• Efficacy of continuous treatment with astemizole (Hismanal) and terfenadine (Seldane) in ragweed pollen-induced rhinoconjunctivitis  Academic Article
• Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty  Academic Article
• Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both  Academic Article
• Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study¹  Academic Article
• Evolving use of new oral anticoagulants for treatment of venous thromboembolism  Academic Article
• Experimental modification of PC12 neurite shape with the microtubule-depolymerizing drug Nocodazole: a serial electron microscopic study of neurite shape control.  Academic Article
• Extended Anticoagulation in Venous Thromboembolism  Academic Article
• Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism  Academic Article
• Extended anticoagulation in venous thromboembolism.  Academic Article
• Extended anticoagulation in venous thromboembolism.  Academic Article
• Extended anticoagulation in venous thromboembolism.  Academic Article
• Factor Xa and thrombin as targets for new oral anticoagulants  Academic Article
• From the hope to the ontarget and the transcend studies: challenges in improving prognosis  Academic Article
• Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies  Academic Article
• Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding  Academic Article
• Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema  Academic Article
• Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk  Academic Article
• Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: Results from the ONTARGET/TRANSCEND Research Programme  Academic Article
• Guanosine-induced decrease in side population of lung cancer cells: lack of correlation with ABCG2 expression.  Academic Article
• Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum  Academic Article
• Home-monitoring of oral anticoagulation vs. dabigatran  Academic Article
• How I treat target-specific oral anticoagulant–associated bleeding  Academic Article
• Idarucizumab for Dabigatran Reversal  Academic Article
• Identification of 2-benzimidazolyl urea as a new antimitotic compound based on cross resistance studies with nocodazole resistant mutants of cho cells  Academic Article
• Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure  Academic Article
• Impact of Sex on Cardiovascular Outcome in Patients at High Cardiovascular Risk  Academic Article
• Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study  Academic Article
• Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme  Academic Article
• Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure  Academic Article
• Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk  Academic Article
• In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events  Academic Article
• In vitro ultraviolet-induced damage in human corneal, lens, and retinal pigment epithelial cells.  Academic Article
• Incidence and Predictors of Hyperkalemia in Patients With Heart Failure  Academic Article
• Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada  Academic Article
• Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients  Academic Article
• Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure  Academic Article
• Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction  Academic Article
• Initial data supporting the design of the Candesartan in Heart failure — Assessment of Reduction in Mortality and morbidity (CHARM) programme  Academic Article
• Intensity and Quality of Warfarin Anticoagulation in Chinese Patients  Academic Article
• International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction  Academic Article
• Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran  Academic Article
• Intravenous proton pump inhibitor therapy: a rationale for use.  Academic Article
• Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial  Academic Article
• Is therapy of people with chronic kidney disease ONTARGET?  Academic Article
• Is there a role for the novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials  Academic Article
• Is there really misuse and abuse of dabigatran?  Academic Article
• Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants  Academic Article
• Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline  Academic Article
• Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study  Academic Article
• Left Ventricular Mass and Volume With Telmisartan, Ramipril, or Combination in Patients With Previous Atherosclerotic Events or With Diabetes Mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET])  Academic Article
• Letter by Van de Werf et al Regarding Article, “Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians”  Academic Article
• Level of Systolic Blood Pressure Within the Normal Range and Risk of Recurrent Stroke  Academic Article
• Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial  Academic Article
• Low salt concentrations activate AMP-activated protein kinase in mouse macula densa cells  Academic Article
• Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin  Academic Article
• Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor  Academic Article
• Management of Anticoagulation Around Pacemaker and Defibrillator Surgery  Academic Article
• Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting  Academic Article
• Mechanisms for perivascular adipose tissue-mediated potentiation of vascular contraction to perivascular neuronal stimulation: The role of adipocyte-derived angiotensin II  Academic Article
• Metabolic effects of telmisartan in subjects with abdominal obesity: A prospective randomized controlled trial  Academic Article
• More on Acutely Injured Patients Receiving Dabigatran  Academic Article
• Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction  Academic Article
• Multidisciplinary Real-World Experience With Bilastine, a Second Generation Antihistamine  Academic Article
• Myocardial Infarction in Heart Failure With Preserved Ejection Fraction  Academic Article
• Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial  Academic Article
• New Anticoagulants for Atrial Fibrillation  Academic Article
• New Anticoagulants for Treatment of Venous Thromboembolism  Academic Article
• New Anticoagulants for the Prevention of Thromboembolism  Academic Article
• New anticoagulants  Conference Paper
• New anticoagulants in atrial fibrillation management  Conference Paper
• New aspects on treatment modalities for thromboembolic episodes  Academic Article
• New oral anticoagulant agents – general features and outcomes in subsets of patients  Academic Article
• New oral anticoagulants and oculoplastic surgery  Academic Article
• New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions  Academic Article
• New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty  Academic Article
• New oral anticoagulants in elderly patients  Academic Article
• New oral anticoagulants: not quite there yet  Academic Article
• New oral anticoagulants: which one should my patient use?  Academic Article
• Newly Identified Events in the RE-LY Trial  Academic Article
• Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics  Academic Article
• Novel Oral Anticoagulants: A Focused Review for Stroke Physicians  Academic Article
• Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism  Academic Article
• Novel oral anticoagulants in gastroenterology practice  Academic Article
• Novel oral anticoagulants in secondary prevention of stroke  Academic Article
• Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits  Academic Article
• Oral Anticoagulant Therapy  Academic Article
• Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects  Academic Article
• Overview of the New Oral Anticoagulants  Academic Article
• Pantoprazole Rapidly Improves Health-Related Quality of Life in Patients With Heartburn  Academic Article
• Patient outcomes using the European label for dabigatran  Academic Article
• Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme  Academic Article
• Percutaneous needle aspiration, injection, and re-aspiration with or without benzimidazole coverage for uncomplicated hepatic hydatid cysts  Academic Article
• Perioperative Management of Dabigatran  Academic Article
• Perioperative management of patients who are receiving a novel oral anticoagulant  Academic Article
• Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin  Academic Article
• Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran  Academic Article
• Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy  Academic Article
• Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran  Academic Article
• Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management  Academic Article
• Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours  Academic Article
• Podophyllotoxin-resistant mutants of Chinese hamster ovary cells: cross-resistance studies with various microtubule inhibitors and podophyllotoxin analogues.  Academic Article
• Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial  Academic Article
• Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation  Academic Article
• Potential of new anticoagulants in patients with cancer  Academic Article
• Practical aspects of new oral anticoagulant use in atrial fibrillation  Academic Article
• Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban  Academic Article
• Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice  Academic Article
• Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation  Academic Article
• Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme  Academic Article
• Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme  Academic Article
• Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran  Academic Article
• Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program  Academic Article
• Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.  Academic Article
• Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction  Academic Article
• Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program  Academic Article
• Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study  Academic Article
• Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate  Academic Article
• Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors  Academic Article
• Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran  Academic Article
• Rationale, Design and Baseline Data of a Randomized, Double-Blind, Controlled Trial Comparing Two Antithrombotic Regimens (a Fixed-Dose Combination of Extended-Release Dipyridamole plus ASA with Clopidogrel) and Telmisartan versus Placebo in Patients with Strokes: The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS)  Academic Article
• Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials  Academic Article
• Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding  Academic Article
• Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure  Academic Article
• Relationship Between Healthy Diet and Risk of Cardiovascular Disease Among Patients on Drug Therapies for Secondary Prevention  Academic Article
• Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial  Academic Article
• Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure  Academic Article
• Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure  Academic Article
• Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial  Academic Article
• Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies  Academic Article
• Reply: regarding the effect of dabigatran plasma concentrations.  Academic Article
• Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme  Academic Article
• Response to Letter Regarding Article, “Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study”  Academic Article
• Response to Letter Regarding Article, “Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis”  Academic Article
• Response to Letter Regarding Article, “Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin”  Academic Article
• Response to Letters Regarding Article, “Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”  Academic Article
• Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.  Academic Article
• Response.  Academic Article
• Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation Chart Audit)  Academic Article
• Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation  Academic Article
• Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS_2 Score: A Subgroup Analysis of the RE-LY Trial  Academic Article
• Rivaroxaban for the prevention and treatment of venous thromboembolism  Academic Article
• SELIMETRY—a multicentre I-131 dosimetry trial: a clinical perspective  Academic Article
• Safety and Efficacy of Dabigatran Compared With Warfarin for Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-analysis  Academic Article
• Safety and Efficacy of Low Blood Pressures Among Patients With Diabetes  Academic Article
• Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review  Academic Article
• Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219  Academic Article
• Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure  Academic Article
• Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: Substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND)  Academic Article
• Stroke Prevention in Atrial Fibrillation Patients With Chronic Kidney Disease  Academic Article
• Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation  Academic Article
• Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy  Academic Article
• Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.  Academic Article
• Systolic Blood Pressure Variation and Mean Heart Rate Is Associated With Cognitive Dysfunction in Patients With High Cardiovascular Risk  Academic Article
• Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction and Stroke in Patients With Coronary Artery Disease  Academic Article
• THE DRUG TREATMENT OF DUODENAL ULCER: PHYSIOLOGICAL CONSIDERATIONS IN THE CHOICE OF THERAPY  Academic Article
• Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events  Academic Article
• Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events  Academic Article
• Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.  Academic Article
• The CHARM program: the effects of candesartan for the management of patients with chronic heart failure  Academic Article
• The CHARM programme  Academic Article
• The Effect of CYP2C19 Polymorphisms on H. pylori Eradication Rate in Dual and Triple First-Line PPI Therapies: A Meta-analysis  Academic Article
• The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients  Academic Article
• The King is Dead (Warfarin): Direct Thrombin and Factor Xa Inhibitors: The Next Diadochian War?  Academic Article
• The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study  Academic Article
• The Mini-Mental State Examination, Clinical Factors, and Motor Vehicle Crash Risk  Academic Article
• The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses  Academic Article
• The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics  Academic Article
• The cost implication of primary prevention in the HOPE 3 trial  Academic Article
• The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study  Academic Article
• The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial  Academic Article
• The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect  Academic Article
• The top 4 advances in antithrombotic care in the last year  Academic Article
• Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding  Academic Article
• Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis  Academic Article
• Treatment of venous thromboembolism with dabigatran  Academic Article
• Usefulness of Temporal Changes in Neurohormones as Markers of Ventricular Remodeling and Prognosis in Patients With Left Ventricular Systolic Dysfunction and Heart Failure Receiving Either Candesartan or Enalapril or Both  Academic Article
• Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.  Academic Article
• Validation of the GSFQ, a Self-Administered Symptom Frequency Questionnaire for Patients with Gastroesophageal Reflux Disease  Academic Article
• Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study  Academic Article
• Venous thromboembolism management: where do novel anticoagulants fit?  Academic Article
• Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin  Academic Article
• Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme  Academic Article
• Well-managed warfarin is superior to NOACs Response  Academic Article
• Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme  Academic Article
• γT‐S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo  Academic Article